Targets › PLK4
1 program from 1 company in 5 trials: 4 Phase 2, 1 Phase 1; Oncology.
Serine/threonine-protein kinase that plays a central role in centriole duplication. Able to trigger procentriole formation on the surface of the parental centriole cylinder, leading to the recruitment of centriole biogenesis proteins such as SASS6, CPAP, CCP110, CEP135 and gamma-tubulin. (UniProt, O00444)
Open in Phaseline: the race on PLK4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Treadwell Therapeutics | CFI-400945 Serine/threonine-protein kinase PLK4 inhibitor | PLK4 | Phase 1 | Acute Myeloid Leukemia; Prostate Cancer; Breast Cancer | – |
Breast Cancer (3) Acute Myeloid Leukemia (1) Prostate Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.